Skip navigation

Integrate Novel Technologies, Strategies and Cross-Functional Approaches to Accelerate Development and Compress Timelines

October 19-20, 2017
  • San Francisco, CA

To achieve ideal timelines, you must accelerate every individual function and handoff utilizing a precise blend of innovative technologies, proven strategies and exceptional project management. The right combination will enable you to successfully go from transfection to IND in less than 12 months. This ambitious goal requires a true team effort from every department.

Speed to IND for Biologics, the first event in CBI’s Bioprocessing Series, provides a comprehensive, cross-functional format that brings together experts from every department to share their perspectives, achievements and lessons learned as a community working towards the common goal of accelerating speed while managing and mitigating risk.

The First Forum Dedicated to Exploring Every Option for Accelerating Speed to IND Submission, Including:

  • Streamline the Transition from R&D to Development
  • Address Cell Line Development Needs Using New Technologies
  • Best Strategies for Increasing Use of Pool Clones for Tox and Clinical Material
  • Determine Best Technologies in Analytical and Process Sciences to Compress Timelines
  • Accelerate Development of New Modalities and Approaches to IND Filing
  • Integrate a Cross-Functional Approach to Successfully Manage Critical Path to IND
  • Address Regulatory and Quality Challenges in Accelerating Timelines
  • Identify Balanced Approaches to Overlapping Activities to Compress Timelines


It will be great to compare notes with industry thought-leaders on the opportunities and challenges of
accelerating biologics development.

President and CEO, Just Biotherapeutics, Inc.

This conference brings together hot topics, key opinion leaders and experts — I am looking forward to learning how the industry is adapting to the realities of today’s environment!

Senior Director, Protein and Cell Sciences, EMD Serono, Inc.

Attending CBI’s Speed to IND for Biologics presents a valuable opportunity to share experiences and bring back the lessons learned from the scientific community to our development team. In this way, we can further refine our approach of developing and transferring robust and scalable processes
with the aim to reduce timelines and mitigate risk.

Development Scientist I, Alexion Pharmaceuticals, Inc.

Regulatory strategies and experiences will be shared and discussed including how to address difficult to “prove”
legacy clonal cell lines.

Associate Research Fellow, Bioprocess R&D, Pfizer Inc

Speed to clinic, including how it is achieved, is one of the key drivers in a biologic’s lifecycle. It impacts everyone in the industry. It’s about time that this topic had a forum
for deep and vibrant discussion.

President, Latham Biopharm Group

I am excited to meet industry leaders who want to push
the boundaries of current practice for bringing
biologics to the patients.

Biologics Expert, Novartis, Switzerland

October 19-20, 2017 Hyatt Centric San Francisco, CA

Bill & Melinda Gates Foundation | Request for Proposal banner